Fat storage, recovery from anoxia, and autophagy-independent survival all show significant improvements from rapamycin treatment specific to the ND2 genotype, and indicate fundamental deficiencies in mitochondrial disease that are rescued with rapamycin. The gene discussed is MT-ND2; the disease is inborn mitochondrial metabolism disorder.